The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR3 (TGFβ receptor 3), also known as BGCAN and Betaglycan, is a transmembrane proteoglycan with a large extracellular domain and a short cytoplasmic domain that lacks an obvious signaling motif. TGFR3 functions as a co-receptor with other TGFBR superfamily members.  It may be involved in capturing and retaining the ligand for presentation to the signaling receptors. TGFBR3 binds TGFβ2 with the highest affinity and other TGFβ isoforms with lower affinities. Cellular responsiveness to TGFβ2 is dependent on the presence of TGFBR3. Ectodomain shedding produces a soluble form of TGFBR3, which binds TGFβ and exhibits antagonistic activity. Reduced expression of TGFBR3 has been observed in various cancers. Genetic variations in TGFBR3 are associated with Vogt-Koyanagi-Harada (VKH) disease and Behcet's disease (BD).

The TGFβ (transforming growth factor β) superfamily proteins are pleiotropic cytokines that regulate a diverse range of cellular processes, including proliferation, differentiation, migration, adhesion and death.  The TGFβ superfamily elicits 4 signaling pathways: TGFβ, Bone Morphogenic Protein (BMP), Activin, and Nodal.  Each pathway signals through a heteromeric receptor complex composed of at least two type-I and two type-II transmembrane receptors containing cytoplasmic serine/threonine kinase domains. These receptors are distinguished by the presence of a glycine/serine-rich juxta-membrane domain found only in the type I receptors. Either type receptor may initially bind ligand, followed by the recruitment of an alternate-type receptor counterpart to form a signal-activating complex. TGFBR3 (TGFβ receptor 3), also known as BGCAN and Betaglycan, is a transmembrane proteoglycan with a large extracellular domain and a short cytoplasmic domain that lacks an obvious signaling motif. TGFR3 functions as a co-receptor with other TGFBR superfamily members.  It may be involved in capturing and retaining the ligand for presentation to the signaling receptors. TGFBR3 binds TGFβ2 with the highest affinity and other TGFβ isoforms with lower affinities. Cellular responsiveness to TGFβ2 is dependent on the presence of TGFBR3. Ectodomain shedding produces a soluble form of TGFBR3, which binds TGFβ and exhibits antagonistic activity. Reduced expression of TGFBR3 has been observed in various cancers. Genetic variations in TGFBR3 are associated with Vogt-Koyanagi-Harada (VKH) disease and Behcet's disease (BD).

 

Product Details

 

Gene Symbol: TGFBR3; TGFBRIII; TGFBR-3; TGFR-3; TGFR-III; BGCAN; betaglycan

 

NCBI Gene ID: 7049

 

Uniprot Entry: Q03167

 

Construct Details: The recombinant human TGFBR3/BGCAN ECD protein is expressed as a 772 amino acid protein consisting of Gly21 - Gly781 region of TGFBR3 (UniProt accession #Q03167) and a C-terminal His tag. 

 

Source: Human cells stably expressing human TGFBR3 and growing in chemical-defined media with no animal components or antibiotics

 

Deduced Amino Acid Sequence: 

GPEPGALCELSPVSASHPVQALMESFTVLSGCASRGTTGLPQEVHVLNLRTAGQGPGQLQ

REVTLHLNPISSVHIHHKSVVFLLNSPHPLVWHLKTERLATGVSRLFLVSEGSVVQFSSA

NFSLTAETEERNFPHGNEHLLNWARKEYGAVTSFTELKIARNIYIKVGEDQVFPPKCNIG

KNFLSLNYLAEYLQPKAAEGCVMSSQPQNEEVHIIELITPNSNPYSAFQVDITIDIRPSQ

EDLEVVKNLILILKCKKSVNWVIKSFDVKGSLKIIAPNSIGFGKESERSMTMTKSIRDDI

PSTQGNLVKWALDNGYSPITSYTMAPVANRFHLRLENNAEEMGDEEVHTIPPELRILLDP

GALPALQNPPIRGGEGQNGGLPFPFPDISRRVWNEEGEDGLPRPKDPVIPSIQLFPGLRE

PEEVQGSVDIALSVKCDNEKMIVAVEKDSFQASGYSGMDVTLLDPTCKAKMNGTHFVLES

PLNGCGTRPRWSALDGVVYYNSIVIQVPALGDSSGWPDGYEDLESGDNGFPGDMDEGDAS

LFTRPEIVVFNCSLQQVRNPSSFQEQPHGNITFNMELYNTDLFLVPSQGVFSVPENGHVY

VEVSVTKAEQELGFAIQTCFISPYSNPDRMSHYTIIENICPKDESVKFYSPKRVHFPIPQ

ADMDKKRFSFVFKPVFNTSLLFLQCELTLCTKMEKHPQKLPKCVPPDEACTSLDASIIWA

MMQNKKTFTKPLAVIHHEAESKEKGPSMKEPNPISPPIFHGSTGHHHHHHHH

  

M.W.: Calculated molecular mass (kDa): 85.7; Estimated by SDS-PAGE under reducing condition (kDa): 95-100

 

Calculated PI: 5.68

 

Calculated extinction coefficients (M-1 cm-1, at 280nm):  68715

 

Purity: >75% judged by SDS-PAGE under reducing condition (see the gel image above, labeled as "DTT: +")

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier & preservative free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Immobilized TGFBR3 protein binds human TGFβ2 in a functional ELISA.  Blocks TGFβ2-mediated signaling activity.

 

 

 

 

  

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

  

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Biochem. Biophys. Res. Commun. 189:356 (1992).

2. J. Hum. Genet. 45:250 (2000).

3. EMBO J. 20 (3): 480-90 (2001).

4. Oncol. Rep. 30:1301-8 (2013).

5. Curr. Eye Res. 37:312 (2012).

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL0239-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.